Who are Dexcom's decision-makers?
Dexcom is led by Jake Leach. Sellers should map decisions across the executive sponsor, business-unit owner, procurement, legal, security, compliance, finance, and operational stakeholders.
- CEO
- Jake Leach
- CFO/key exec
- Kevin Sayer
- Founded
- 1999
- Employees
- 10,000+
- HQ
- San Diego, CA
- Status
- Nasdaq: DXCM
- Jake LeachChief Executive OfficerCEO effective January 2026Former president and COO leading Dexcom's next phase after Kevin Sayer.
- Kevin SayerExecutive ChairmanCEO 2015-2025; Executive Chairman since 2026Longtime CEO supporting continuity after the leadership transition.
- Jereme SylvainExecutive Vice President and Chief Financial OfficerCFO since 2021Finance leader through CGM scale-up and Stelo launch.
- Teri LawverChief Commercial OfficerSenior executive leadershipCommercial leader for global CGM adoption and market access.
Who leads Dexcom?
Dexcom's leadership team combines enterprise healthcare operations, finance, clinical, product, technology, legal, and commercial roles. The CEO and CFO set capital priorities, while business-unit leaders decide which operational problems become funded initiatives.
Who actually makes buying decisions at Dexcom?
Buying decisions usually start with a business-unit sponsor, then move through procurement, finance, legal, data-security, compliance, privacy, and implementation owners. Clinical, reimbursement, or quality stakeholders become essential whenever the purchase touches patient care, regulated data, medical products, or payer/provider economics.
How is Dexcom organized as it scales?
Dexcom operates through business units tied to Continuous glucose monitoring sensors, transmitters, receivers, apps, and data services. That creates multiple entry points, but enterprise standards for security, compliance, contracting, and vendor management can still control the final approval path.
As of June 2026.Sources:Dexcom leadershipDexcom annual reports
Dexcom — frequently asked questions
